Jacques Raphael

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 13

Top Topics

Small Cell Lung Cancer

Radiation Therapy

Liver Metastases

Top Venues

Current oncology (Toronto, Ont.)

JCO oncology practice

This page only lists publications with an associated author ORCID identifier.

Publications

Saurav Verma, Daniel A Breadner, Abhenil Mittal, David A Palma, Rahul Nayak, Jacques Raphael, Mark Vincent
An Updated Review of Management of Resectable Stage III NSCLC in the Era of Neoadjuvant Immunotherapy. Cancers 16 (7) (2024)
Freeman Paczkowski, Jacques Raphael, Claire Browne
Durable Response to Atezolizumab in Extensive-Stage Small-Cell Lung Cancer Leading to 60 Months Overall Survival: A Case Report. Current oncology (Toronto, Ont.) 31 (7) (2024)
Claire Browne, Toufic Ayoub, Nadeesha Samarasinghe, Syed Hussaini, Andrew Warner, Morgan Black, David A Palma, Jacques Raphael, Sara Kuruvilla, Phillip S Blanchette
Impact of an Etoposide Chemotherapy Shortage on Patients With Extensive-Stage Small-Cell Lung Cancer: Results of a Natural Experiment. JCO oncology practice (2024)
Saurav Verma, Daniel A Breadner, Abhenil Mittal, David A Palma, Rahul Nayak, Jacques Raphael, Mark Vincent
An Updated Review of Management of Resectable Stage III NSCLC in the Era of Neoadjuvant Immunotherapy. Cancers 16 (7) (2024)
Saurav Verma, Daniel A Breadner, Abhenil Mittal, David A Palma, Rahul Nayak, Jacques Raphael, Mark Vincent
An Updated Review of Management of Resectable Stage III NSCLC in the Era of Neoadjuvant Immunotherapy. Cancers 16 (7) (2024)
Freeman Paczkowski, Jacques Raphael, Claire Browne
Durable Response to Atezolizumab in Extensive-Stage Small-Cell Lung Cancer Leading to 60 Months Overall Survival: A Case Report. Current oncology (Toronto, Ont.) 31 (7) (2024)
Freeman Paczkowski, Jacques Raphael, Claire Browne
Durable Response to Atezolizumab in Extensive-Stage Small-Cell Lung Cancer Leading to 60 Months Overall Survival: A Case Report. Current oncology (Toronto, Ont.) 31 (7) (2024)
Saurav Verma, Daniel A Breadner, Jacques Raphael
'Targeting' Improved Outcomes with Antibody-Drug Conjugates in Non-Small Cell Lung Cancer-An Updated Review. Current oncology (Toronto, Ont.) 30 (4) (2023)
Saurav Verma, Daniel A Breadner, Jacques Raphael
'Targeting' Improved Outcomes with Antibody-Drug Conjugates in Non-Small Cell Lung Cancer-An Updated Review. Current oncology (Toronto, Ont.) 30 (4) (2023)
Ricardo Fernandes, Terry L Ng, Mashari Jemaan Alzahrani, Jacques Raphael, Phillip Blanchette, Morgan Black, Carol Stober, Gregory R Pond, David Cella, Lisa Vandermeer, Mohammed Ibrahim, Mark J Clemons, null null
A Multi-Centre Randomized Study Comparing Two Standard of Care Chemotherapy Regimens for Lower-Risk HER2-Positive Breast Cancer. Current oncology (Toronto, Ont.) 30 (8) (2023)
Saurav Verma, Daniel A Breadner, Jacques Raphael
'Targeting' Improved Outcomes with Antibody-Drug Conjugates in Non-Small Cell Lung Cancer-An Updated Review. Current oncology (Toronto, Ont.) 30 (4) (2023)
Danilo Giffoni de Mello Morais Mata, Rania Chehade, Malek B Hannouf, Jacques Raphael, Phillip Blanchette, Abdullah Al-Humiqani, Monali Ray
Appraisal of Systemic Treatment Strategies in Early HER2-Positive Breast Cancer-A Literature Review. Cancers 15 (17) (2023)
Jacques Raphael, Lucie Richard, Melody Lam, Phillip S Blanchette, Natasha B Leighl, George Rodrigues, Maureen E Trudeau, Monika K Krzyzanowska
Utilization of Immunotherapy in Patients with Cancer Treated in Routine Care Settings: A Population-Based Study Using Health Administrative Data. The oncologist 27 (8) (2022)